Liver transplantation in metabolic dysfunction-associated steatotic liver disease: Current evidence and unresolved issues

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become one of the leading indications for liver transplantation (LT). In this review, we summarize the current evidence on LT for MASLD across the transplant cycle, from candidate evaluation to long-term management. Candidates with MASLD have a high prevalence of coronary artery disease, and anatomic coronary imaging is increasingly recommended as the initial strategy in this population. Frailty and sarcopenia are complementary measures of risk, and functional assessment may add to imaging-based assessment of muscle mass in this population. Body mass index alone should not exclude a patient from evaluation. Bariatric surgery, preferably sleeve gastrectomy performed before or at the time of LT, is an option for selected candidates with severe obesity. The progression of the Model for End-Stage Liver Disease score in these patients is driven disproportionately by renal dysfunction, and lower transplant rates and higher waitlist mortality have been reported. On the donor side, hepatic steatosis is a common but potentially reversible barrier to living donation, and short-term weight reduction enables a substantial proportion of initially unsuitable candidates to proceed to donation, although long-term outcomes of these donors remain to be defined. After LT, adjusted registry analyses have not identified MASLD as an independent predictor of poorer survival, and recurrence of hepatocellular carcinoma has not increased; however, recurrent steatosis and de novo metabolic syndrome are frequent, and evidence on pharmacotherapy in transplant recipients is only beginning to emerge. Unresolved issues include the misclassification of MASLD and metabolic dysfunction and alcohol-associated liver disease in transplant registries, standardized thresholds for donor steatosis, and the potential role of donor genotype in graft steatosis.

Authors

Institutions

Publication Details

Journal
Annals of Liver Transplantation
Published
2026-11-17
DOI
https://doi.org/10.52604/alt.26.0022
Primary Topic
Organ Transplantation Techniques and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Liver transplantation in metabolic dysfunction-associated steatotic liver disease: Current evidence and unresolved issues

Moon Haeng Hur
2 links
Annals of Liver Transplantation
Organ Transplantation Techniques and Outcomes
article

Liver transplantation in metabolic dysfunction-associated steatotic liver disease: Current evidence and unresolved issues

Moon Haeng Hur
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become one of the leading indications for liver transplantation (LT). In this review, we summarize the current evidence on LT for MASLD across the transplant cycle, from candidate evaluation to long-term management. Candidates with MASLD have a high prevalence of coronary artery disease, and anatomic coronary imaging is increasingly recommended as the initial strategy in this population. Frailty and sarcopenia are complementary measures of risk, and functional assessment may add to imaging-based assessment of muscle mass in this population. Body mass index alone should not exclude a patient from evaluation. Bariatric surgery, preferably sleeve gastrectomy performed before or at the time of LT, is an option for selected candidates with severe obesity. The progression of the Model for End-Stage Liver Disease score in these patients is driven disproportionately by renal dysfunction, and lower transplant rates and higher waitlist mortality have been reported. On the donor side, hepatic steatosis is a common but potentially reversible barrier to living donation, and short-term weight reduction enables a substantial proportion of initially unsuitable candidates to proceed to donation, although long-term outcomes of these donors remain to be defined. After LT, adjusted registry analyses have not identified MASLD as an independent predictor of poorer survival, and recurrence of hepatocellular carcinoma has not increased; however, recurrent steatosis and de novo metabolic syndrome are frequent, and evidence on pharmacotherapy in transplant recipients is only beginning to emerge. Unresolved issues include the misclassification of MASLD and metabolic dysfunction and alcohol-associated liver disease in transplant registries, standardized thresholds for donor steatosis, and the potential role of donor genotype in graft steatosis.

Annals of Liver Transplantation
Seoul National University (KR)
Good health and well-being
Organ Transplantation Techniques and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon